Quick Answer
Tempest Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $7.71 million for the year ending 2025.
- Tempest Therapeutics, Inc. showed a decrease of -74.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Tempest Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 69.7%.
- Historical annual values: Fiscal year 2025: $7.71 million | Fiscal year 2024: $30.27 million | Fiscal year 2023: $39.23 million | Fiscal year 2022: $31.23 million | Fiscal year 2021: $51.83 million | Fiscal year 2020: $18.82 million | Fiscal year 2019: $62.48 million | Fiscal year 2018: $73.29 million | Fiscal year 2017: $17.58 million | Fiscal year 2016: $43.93 million | Fiscal year 2015: $43.22 million | Fiscal year 2014: $6.41 million | Fiscal year 2013: $18.08 million | Fiscal year 2012: $14.78 million | Fiscal year 2011: $4.54 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: